Roche Developing Diagnostic Assay To Predict Xeloda Response
Roche is developing a tumor-specific assay to target the metastatic breast cancer therapy Xeloda (capecitabine) to patients more likely to respond.
Roche is developing a tumor-specific assay to target the metastatic breast cancer therapy Xeloda (capecitabine) to patients more likely to respond.